



**For Immediate Release**  
**January 11, 2017**

**SUNSHINE BIOPHARMA CURRENTLY REVIEWING TWENTY THREE ADDITIONAL GENERIC PRODUCTS FOR IN-LICENSING**

Montreal, QC – (Marketwired – January 11, 2017) – Sunshine Biopharma Inc. (OTCQB: SBFM), a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications, is pleased to announce that it currently has Twenty Three additional Generic Pharmaceuticals under review for in-licensing. When completed, this will bring the Company's Generic Products portfolio to a total of Twenty Seven. A larger products portfolio provides the Company with more opportunities and a greater reach into the marketplace. Sunshine will market and sell these new pharmaceutical products under its own label.

Sunshine's current Generic Products portfolio is comprised of the following:

- Anastrozole (brand name Arimidex® by AstraZenica) for treatment of Breast Cancer
- Letrozole (brand name Femara® by Novartis) for treatment of Breast Cancer
- Bicalutamide (brand name Casodex® by AstraZenica) for treatment of Prostate Cancer
- Finasteride (brand name Propecia® by Merck) for treatment of BPH (Benign Prostatic Hyperplasia)

Worldwide sales of the brand name version of these products as reported by the respective owner of the registered trademark are as follows:

- Arimidex® \$250M in 2015
- Femara® \$380M in 2014
- Casodex® \$267M in 2015
- Propecia® \$183M in 2015

Sunshine is currently moving forward with the procurement of a Drug Identification Number ("DIN") for each of these products and a Drug Establishment License ("DEL") for its new facility secured through the Company's recently announced Strategic Alliance Agreement.

Revenues from sales of Generic Products are intended to be used to finance the Company's proprietary drug development program including Adva-27a, the Company's flagship anticancer compound. A Topoisomerase II inhibitor, Adva-27a is a small molecule that has recently been shown to be effective at destroying Multidrug Resistant Breast Cancer cells, Pancreatic Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Sunshine Biopharma is direct owner of all issued and pending worldwide patents pertaining to Adva-27a including U.S. Patent Number 8,236,935.

**Safe Harbor Forward-Looking Statements**

*To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals,*

*future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.*

**For Additional Information:**

Sunshine Biopharma Inc.  
Camille Sebaaly, CFO  
Direct Line: 514-814-0464  
[camille.sebaaly@sunshinebiopharma.com](mailto:camille.sebaaly@sunshinebiopharma.com)